HC Wainwright & Co. Reiterates Buy on Vertex Pharmaceuticals, Maintains $380 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a $380 price target.
June 26, 2023 | 10:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals and maintained a $380 price target.
The reiteration of a Buy rating and maintenance of a $380 price target by HC Wainwright & Co. analyst Andrew Fein indicates a positive outlook for Vertex Pharmaceuticals. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100